THERAPEUTIC POTENTIAL OF PHYTOCANNABINOIDS IN MODULATING NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES
Abstract
Neurodegenerative diseases represent a critical challenge to global public health, demanding therapies that transcend symptomatic management. This integrative review investigates the therapeutic potential of phytocannabinoids in modulating chronic neuroinflammation. Methodology: this review was based on the analysis of evidence from the last five years extracted from the PubMed/MEDLINE and LILACS databases regarding the modulation of inflammation in neurodegenerative pathologies. Results: Phytocannabinoid compounds appear to act pleiotropically, promoting blood-brain barrier protection, rescuing autophagic flux, and reducing pro-inflammatory cytokines. Conclusion: The administration of these compounds offers a promising neuroprotective strategy, although clinical standardization and overcoming regulatory barriers are essential for their universal therapeutic viability.
Author Biographies
Ph.D. candidate in Health Sciences at the University of Southern Santa Catarina (UNISUL).
Graduated in Medicine from the Federal University of Jataí (UFJ).
Graduado em Medicina (Universidade Federal do Piauí – UFPI).
Graduated in Medicine from Nove de Julho University.
Graduated in Medicine from PUC-SP (Pontifical Catholic University of São Paulo).
Graduated in Medicine from Atenas University Center.
Medical student at the University of Rio Verde.
Graduated in Nursing from Nove de Julho University (UNINOVE), Specialist in Clinical Research and Family Health Strategy (DNA Postgraduate / COREN), and currently a postgraduate student in Adult Neurofunctional Multidisciplinary Rehabilitation at the Municipal University of São Caetano do Sul (USCS).
Specialist in Health Surveillance and Care in Coping with COVID-19 and other Diseases from Fiocruz Mato Grosso do Sul (FIOCRUZ-MS). Current institution: Federal University of Piauí.
References
AHMED, H. et al. Metabólitos derivados da microbiota como impulsionadores da comunicação intestino-cérebro. Micróbios intestinais, v. 14, n. 2102878, 2022.
AHLUWALIA, M. et al. Metabolismo endocanabinóide alterado compromete a barreira hematoencefálica e exacerba déficits crônicos após lesão cerebral traumática em camundongos. Exp. Neurol., v. 361, n. 114320, 2023.
ALVES, A. D. F. et al. Use of phytocanabinoids in animal models of Parkinson's disease: Systematic review. Neurotoxicology, v. 105, p. 34-44, 2024.
ANDERSON, L. L. et al. Farmacocinética dos ácidos fitocanabinoides e efeito anticonvulsivante do ácido canabidiólico em um modelo murino da síndrome de Dravet. Journal of Natural Products, v. 82, n. 11, p. 3047–3055, 2019.
ANIL, S. M.; PEERI, H.; KOLTAI, H. Atividade da Cannabis Medicinal contra a Inflamação: Compostos Ativos e Modos de Ação. Front. Pharmacol., v. 13, n. 908198, 2022.
BEN-SHABAT, S. et al. Cannabinoids, the Blood–Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives. Biomolecules, v. 16, n. 2, p. 225, 2026.
BELTRÁN-VELASCO, A. I.; CLEMENTE-SUÁREZ, V. J. Impact of peripheral inflammation on blood-brain barrier dysfunction and its role in neurodegenerative diseases. Int. J. Mol. Sci., v. 26, n. 2440, 2025.
BHUNIA, S. et al. Cannabidiol for Neurodegenerative Disorders: A Comprehensive Review. Frontiers in Pharmacology, v. 13, p. 98971, 2022.
BLEBEA, N.-M. et al. Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders. Pharmaceuticals, v. 18, n. 6, p. 890, 2025.
CHAGAS, M. H. et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. Journal of Psychopharmacology, v. 28, n. 11, p. 1088-1098, 2014.
CHEN, L. et al. Assessing cannabidiol as a therapeutic agent for preventing and alleviating Alzheimer's disease neurodegeneration. Cells, v. 12, n. 23, p. 2672, 2023.
COLES, M. et al. Chronic treatment with medium-dose cannabidiol reverses object recognition memory deficits in female APPSwe/PS1ΔE9 mice. Frontiers in Pharmacology, v. 11, p. 587604, 2020.
CURY, R. de M. et al. A randomized clinical trial of low-dose cannabis extract in Alzheimer’s disease. J. Alzheimer’s Dis., v. 138, p. 1387-1389, 2025.
DA SILVA, V. K. et al. Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. Brain Research Bulletin, v. 139, p. 1-8, 2018.
DANZIGER, N.; BERNSTEIN, N. Light Matters: Effect of Light Spectra on Cannabinoid Profile and Plant Development of Medical Cannabis. Industrial Crops and Products, v. 164, n. 113351, 2021.
DE PAULA FARIA, D. et al. Cannabidiol treatment improves glucose metabolism and memory in streptozotocin-induced alzheimer's disease rat model. International Journal of Molecular Sciences, v. 23, n. 3, p. 1076, 2022.
DUDEK, K. A. et al. O receptor canabinóide astrocítico 1 promove a resiliência ao atenuar as alterações da barreira hematoencefálica induzidas pelo estresse. Nat. Neurosci., v. 28, p. 766–782, 2025.
ESPADAS, I. et al. Beneficial effects of the phytocannabinoid Δ9-THCV on L-DOPA-induced dyskinesia in Parkinson’s disease. Neurobiology of Disease, v. 141, p. 104892, 2020.
EVANS, C. S.; HOLZBAUR, E. L. F. Quality control in neurons: mitophagy and other selective autophagy mechanisms. J. Mol. Biol., v. 432, n. 1, p. 240–260, 2020.
FOCK, E.; PARNOVA, R. Mecanismos de proteção da barreira hematoencefálica por ácidos graxos de cadeia curta derivados da microbiota. Cells, v. 12, n. 657, 2023.
GIULIANO, C. et al. Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson’s disease. International Journal of Molecular Sciences, v. 22, n. 16, p. 8920, 2021.
GUADALUPI, L. et al. O bloqueio farmacológico da degradação de 2-AG atenua as alterações clínicas, neuroinflamatórias e sinápticas na encefalomielite autoimune experimental. Neuropharmacology, v. 252, n. 109940, 2024.
HAO, F.; FENG, Y. Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer’s mice. Life Sciences, v. 264, p. 118624, 2021.
HASBI, A.; GEORGE, S. R. Neuroproteção multicamadas por canabinoides em doenças neurodegenerativas. Explor. Neuroprot. Ther., v. 5, n. 100498, 2025.
HERMUSH, V. et al. Effects of cannabidiol-rich oil on behavioral disturbances in patients with dementia: a placebo-controlled randomized clinical trial. Frontiers in Medicine, v. 9, p. 951889, 2022.
HUANG, X. et al. Inflamação periférica e ruptura da barreira hematoencefálica: efeitos e mecanismos. CNS Neurosci. Ther., v. 27, p. 36–47, 2021.
JIANG, X. et al. Cannabidiol protects the BBB through PPARγ. Biomed. Pharmacother., 2021.
JURGA, M. et al. Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. International Journal of Molecular Sciences, v. 25, n. 20, p. 11258, 2024.
KANG, S. et al. Cannabidiol induces autophagy to protects neural cells from mitochondrial dysfunction by upregulating SIRT1. Front. Cell Neurosci., v. 15, n. 654340, 2021.
KIM, J. et al. Cannabinoids CBDA and THCA rescue memory deficits and reduce amyloid-beta and tau pathology in an Alzheimer’s-like mouse model. International Journal of Molecular Sciences, v. 24, n. 7, p. 6827, 2023.
LACERDA, M. et al. Farmacocinética de fitocanabinoides não psicotrópicos. Pharmaceutics, v. 17, n. 2, 2025.
LANGEN, U. H. et al. Desenvolvimento e biologia celular da barreira hematoencefálica. Annu. Rev. Cell Dev. Biol., v. 35, p. 591–613, 2019.
LAZARJANI, M. P. et al. Processing and Extraction Methods of Medicinal Cannabis: A Narrative Review. Journal of Cannabis Research, v. 3, n. 32, 2021.
MOU, Y. et al. A microbiota intestinal interage com o cérebro por meio da inflamação crônica sistêmica. Front. Immunol., v. 13, n. 796288, 2022.
NTSAPI, C. et al. Exploring cannabinoid modulation on autophagy mechanisms in Alzheimer's disease: a review. Frontiers in Pharmacology, v. 16, p. 1748368, jan. 2026.
NUNEZ-LUMBRERAS et al. Cannabinoid receptors and BBB permeability. Neurochem. Int., 2020.
PAES-COLLI, Y. et al. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in Cellular Neuroscience, v. 16, p. 917164, 2022.
PALOMARES, B. et al. THCA is a potent PPARγ agonist. Br. J. Pharmacol., 2020.
PFAU, S. J. et al. Características da heterogeneidade da barreira hematoencefálica entre regiões cerebrais reveladas pela análise de células vasculares e perivasculares. Nat. Neurosci., v. 27, p. 1892–1903, 2024.
PIMENTEL, E. G.; LEME, R. S. Canabinoides e Neuroproteção em Idosos. Arace, 2026.
RAKOTOARIVELO, V. et al. The impact of the cannabinoid receptor CB2 in inflammatory diseases: an update. Molecules, v. 29, n. 14, p. 3381, 2024.
RUVER-MARTINS, A. C. et al. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer’s disease symptoms: a case report. J. Med. Case Rep., v. 16, n. 1, p. 277, 2022.
SAINZ MARTINEZ, A. et al. Extraction Techniques for Bioactive Compounds of Cannabis. Natural Product Reports, v. 40, p. 676–717, 2023.
SÁNCHEZ-FERNÁNDEZ, N. et al. A combination of Δ9-tetrahydrocannabinol and cannabidiol modulates glutamate dynamics in the hippocampus. Neurotherapeutics, v. 21, n. 5, p. e00439, 2024.
SCUDERI, C. et al. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytotherapy Research, v. 28, n. 7, p. 1007-1013, 2014.
SINGH, S. K. et al. Therapeutic potential of acidic cannabinoids: an update. Journal of Cannabis Research, jan. 2026.
SKRZYPCZAK-WIERCIOCH, A.; SAŁAT, K. Modelo de neuroinflamação induzida por lipopolissacarídeo: mecanismos de ação, aplicação em pesquisa e direções futuras. Molecules, v. 27, n. 5481, 2022.
SMITH, S. et al. Fitocanabinoides — Avaliação de seu papel terapêutico na neuroinflamação. Explor. Neuroprot. Ther., v. 4, p. 325–348, 2024.
SOMOGYI, P. et al. Synaptic targets and cellular sources of nerve terminals expressing the cannabinoid CB1 receptor. European Journal of Neuroscience, v. 61, p. e16652, 2025.
SUZUKI, S. et al. O ácido canabigerólico (CBGA) inibe o canal iônico TRPM7 através de seu domínio quinase. Function, v. 5, n. 1, p. zqad069, 2024.
VELAYUDHAN, L. et al. Cannabidiol for behavioral symptoms in Alzheimer's disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial. International Psychogeriatrics, v. 36, n. 8, p. 1270-1272, 2024.
VITALE, R. M. et al. Identificação dos ácidos canabidiólico e canabigerólico como inibidores de MTDL AChE, BuChE e BACE-1 contra a doença de Alzheimer. Phytotherapy Research, v. 39, n. 1, p. 233–245, 2025.
VRECHI, T. A. M. et al. Cannabidiol induces autophagy via ERK1/2 activation in neural cells. Sci. Rep., v. 11, n. 5434, 2021.
WANG, Z. et al. Cannabidiol induces autophagy and improves neuronal health associated with SIRT1 mediated longevity. GeroScience, v. 44, n. 3, p. 1505–1524, 2022.
WU, S.; RAJIAH, T.; ALI, A. B. Therapeutic Potential for Cannabidiol on Alzheimer's Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, v. 26, n. 24, p. 11963, 2025.
ZHANG, Q. et al. Δ9-Tetrahidrocanabinol Induz Disrupção da Barreira Hematoencefálica: Envolvendo a Ativação do CB1R e Estresse Oxidativo. Neuropharmacology, v. 270, n. 110366, 2025.
ZHENG, X. et al. Proteínas de junção estreita relacionadas à barreira hematoencefálica e suas vias de sinalização regulatórias no acidente vascular cerebral isquêmico. Biomed. Pharmacother., v. 165, n. 115272, 2023.
License
Copyright (c) 2026 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.